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SCH-27899 is an investigational antibiotic from the everninomicin family, a
group of oligosaccharide antibiotics produced by Micromonospora carbonacea.
Information regarding the pharmacology, pharmacodynamics,
pharmacokinetics, efficacy, and toxicity of this agent was obtained from a
MEDLINE search and a review of abstracts presented at recent scientific
meetings.  SCH-27899 has in vitro bacteriostatic activity against a wide variety
of gram-positive organisms, including highly resistant organisms such as
methicillin-resistant Staphylococcus aureus, vancomycin-intermediate-
sensitivity S. aureus, Streptococcus pneumoniae (both penicillin-susceptible and
-nonsusceptible), and vancomycin-resistant enterococci.  In vitro data, animal
studies, and preliminary human studies indicate that it is effective and fairly
well tolerated.  Its place in therapy remains to be determined, and clinical
trials continue.
(Pharmacotherapy 1999;19(10):1111–1117)
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SCH-27899 (Ziracin; Schering-Plough Research
Institute, Kenilworth, NJ) is an investigational
antibiotic from the everninomicin family.  The
everninomicins are oligosaccharide antibiotics
produced by Micromonospora carbonacea, which
consists of at least five distinct compounds
(everninomicins A, B, C, D, E) that have activity
against gram-positive organisms.1 Everninomicin
D is the most active of these compounds and is
highly active against gram-positive bacteria; it is
the D component to which SCH-27899 is most
closely related.1–3 The antimicrobial potential of
the compounds was first recognized over 30
years ago, but emergence of widespread microbial
resistance to commonly prescribed antimicrobial
agents has sparked a new interest.
Chemical Characteristics and Pharmacology
Everninomicins have several unusual
structural features, such as the presence of ortho
ester functionalities, an aliphatic methylene
dioxy group, a nitro sugar, and a fully substituted
phenolic ester residue.4 The structure of SCH-
27899 (C70H97NO38Cl2) is shown in Figure 1.  It
is an amorphous solid with an estimated
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molecular weight of 1629 d.3
The mechanism of antibacterial action of the
everninomicins is not well described, although it
is believed that the agents act to inhibit protein
synthesis.  In a recent investigation of Staphylococcus
aureus isolates exposed to SCH-27899, in vivo
incorporation of isoleucine was markedly
reduced.  As incorporation of other substrates
(thymidine, uracil, N-acetylglucosamine, acetate)
was not affected to the same extent as isoleucine,
the authors concluded that this is consistent with
the hypothesis that the drug inhibits protein
synthesis.5 By identifying a point mutation
common to strains of Streptococcus pneumoniae
resistant to SCH-27899, it was theorized that the
drug’s target site is ribosomal protein L16, located
at the interface of the large and small ribosomal
subunits.6 The proposed mechanism of action
involves a ribosomal target; thus it is likely that
the agent’s actions are concentration independent.
Spectrum of Antibacterial Activity and
Pharmacodynamics
Since the compounds were first isolated, it was
recognized that everninomicin D is highly active
against many gram-positive organisms, with little
or no gram-negative activity, an observation that
was confirmed in later studies.1, 2 More recent
studies with SCH-27899 showed in vitro
antibacterial activity against a wide variety of
gram-positive organisms, with bacteriostatic
actions on methicillin-sensitive S. aureus (MSSA),
methicillin-resistant S. aureus (MRSA),
vancomycin-intermediate-susceptibility S. aureus
(VISA), methicillin-sensitive Staphylococcus
epidermidis (MSSE), methicillin-resistant S.
epidermidis (MRSE), penicillin-susceptible and -
nonsusceptible strains of S. pneumoniae, Streptococcus
pyogenes, vancomycin-sensitive enterococci,
vancomycin-resistant enterococci (VRE), Listeria
monocytogenes, Clostridium jeikium, and
Clostridium difficile.7–9
The antimicrobial activity of the agent
compared with that of vancomycin is shown in
Table 1.  In comparative studies, the activity of
SCH-27899 was consistently better than that of
vancomycin for the organisms listed.7, 8 In vitro
activity of SCH-27899 was compared against a
variety of enterococci species (including VRE)
with that of several agents, most notably, the
investigational RP-59500 (quinupristin-
dalfopristin, Synercid; Rhône-Poulenc Rorer,
Collegeville, PA), vancomycin, and teicoplanin.10
The minimum inhibitory concentrations for 90%
of tested strains (MIC90) for SCH-27899
(0.25–0.5 µg/ml) were at least 4-fold lower than
those of RP-59500 (2.0–16 µg/ml) in all species
tested.  Values for vancomycin were 4.0–512
µg/ml and those for teicoplanin were 0.5–128
µg/ml or below.  When SCH-27899 was
compared with levofloxacin, trovafloxacin,
ciprofloxacin, and sparfloxacin, it had superior in
vitro activity (higher therapeutic index, based on
comparison with ratios of drug concentration
and MIC) against penicillin-intermediately
susceptible and penicillin-nonsusceptible strains
of S. pneumoniae.11
In addition, SCH-27899 appears to have
substantial in vitro activity against Legionella
sp.12, 13 In a study of 104 Legionella sp, its MIC90
was 0.25 µg/ml, comparable with those of
ofloxacin (0.06 µg/ml) and erythromycin (0.05
µg/ml).  In an in vitro investigation involving
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Figure 1. Structural formula of SCH-27899.
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anaerobic organisms, SCH-27899 had significant
antibacterial activity against Peptostreptococcus sp
(MIC50 < 0.25 µg/ml) and was active against
Porphyromonas sp (MIC50 2 µg/ml; it was less
active than piperacillin, clarithromycin,
clindamycin, and metronidazole).  However,
SCH-27899 had poor activity against Bacteroides
fragilis and Fusobacterium nucleatum.14 It had in
vitro activity against Borrelia burgdorferi,
comparable with those of penicillin and
ceftriaxone (MIC90 0.1–0.5, 0.5–2, and 0.1–0.25
µg/ml, respectively).15
The agent does not appear to have appreciable
in vitro activity against atypical organisms; its
MIC90 against Mycoplasma pneumoniae was 16
µg/ml, and the compound was less active than
macrolides and fluoroquinolones.16 Similarly,
MIC90 values for SCH-27899 were 8.0 µg/ml
against Chlamydia pneumoniae and Chlamydia
trachomatis.17 SCH-27899 was less active than
doxycycline and erythromycin against both
Chlamydia sp.
Attempts were made to quantify the post-
antibiotic effect (PAE) of SCH-27899.  The drug
was removed through a 1/100 dilution in
antibiotic-free Mueller Hinton broth after 1-hour
exposure to bacterial isolates.7 The PAE was
quantified by performing viable cell counts every
hour for 8 hours and comparing the difference in
time required by test and control cultures to
increase 1 log10 colony-forming unit (CFU)/ml
after the drug was removed.  At a concentration
of 4 times its MIC, the PAE of SCH-27899 was
1.8 hours against S. aureus and 2.6 hours against
E. faecalis.  These values were slightly longer
than those of vancomycin for the same organisms
(1.5 and 2.2 hrs, respectively).  It is unlikely,
however, that this difference in PAE is of clinical
significance.
Studies examined the in vitro activity of SCH-
27899 in combination with other drugs.
Seventeen antimicrobial agents were screened for
either synergy or antagonism with SCH-27899 in
a collection of 110 bacterial isolates representing
31 species or subgroups.18 No evidence of either
antagonism or synergy was observed, with one
potential exception; the addition of  SCH-27899
to ampicillin produced at least a 4-fold decrease
in ampicillin MICs in four of six methicillin-
susceptible staphylococci isolates.  Unfortunately,
this study is published only in abstract form and
does not report the investigators’ detailed
methods.  Others have examined combined
antimicrobial activity of SCH-27899 with various
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Table 1.  Comparative In Vitro Susceptibilities of SCH-27899 and Vancomycin
MIC90a (range, µg/ml)
Organism SCH-27899 Vancomycin
S. aureus
Methicillin susceptible 0.44 (0.05–0.5) 0.75 (0.2–2)
Methicillin resistant 0.66 (0.05–0.5) 0.75 (0.2–4)
VISAb 0.5 4.0
Coagulase-negative staphylococcic
Methicillin susceptible 0.66 (0.25–0.78) 2.37 (0.1–4)
Methicillin resistant 0.66 (0.1–3.13) 2.65 (0.1–3.13)
Enterococci
Vancomycin susceptibled 0.25 (< 0.125–0.5) 2.0 (0.5–2.0)
E. faecalis7 0.2 (0.05–0.39) 1.56 (0.2–3.13)
E. faecium7 0.39 (0.05–0.39) 1.56 (0.01–1.56)
E. avium7 0.2 (0.05–0.39) 0.39 (0.1–0.78)
Vancomycin resistante 0.25 (< 0.125–0.5) > 8.0 (8.0 to > 8.0)
Streptococcus pyogenes 0.113 (< 0.025 to < 0.125) 0.32 (0.1–0.5)
Streptococcus pneumoniae 0.111 (< 0.025 to < 0.125) 0.50 (0.1–0.78)
Streptococcus agalactiae 0.111 (< 0.025 to < 0.2) 0.554 (< 0.125–0.78)
Streptococcus group C8 < 0.125 (< 0.125) 0.25 (0.25–0.5)
Streptococcus group G8 < 0.125 (< 0.125) 0.125 (< 0.125–0.125)
Clostridium jeikium8 < 0.125 (< 0.125) < 0.125 (< 0.125)
Clostridium difficile7 0.2 (0.05–0.2) 1.56 (0.1–1.56)
Listeria monocytogenes8 < 0.125 (< 0.125–0.25) 0.5 (0.25–0.5)
aMIC90 = minimum inhibitory concentration for 90% of strains tested7–9; where possible, it represents a weighted
average of information from references 7 and 8.
bVancomycin-intermediate-susceptibility S. aureus (no ranges reported).9
cIsolates tested were S. epidermidis, S. saprophyticus, S. hominis, and S. capitis,5 and S. epidermidis only.7
dE. faecium and E. faecalis.8
eE. faecium only.8
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b-lactam antibiotics and fosfomycin (an
antibiotic produced by Streptomyces strains)
against strains of MRSA and MRSE using the
microdilution checkerboard method.7 Synergy
(30–56% of strains), additive effects (11–37%),
or indifference (19–37%) was observed with all
combinations, with no evidence of antagonism.
A study was conducted that examined the
effect of changes in the growth medium on the in
vitro actions of SCH-27899.  It demonstrated that
minor changes in inoculum (a decrease of 103
CFU/spot or an increase of 105 CFU/spot), an
increased magnesium concentration, and an
alkaline pH (pH = 8) resulted in less than a 2-fold
change in the agent’s MIC values.19 These values
showed no change or up to a 4-fold decrease
when the agent was placed in an acidic
environment (pH = 6), incubated in an anaerobic
environment, and incubated in the presence of
5% carbon dioxide.  Increasing the inoculum to
greater than 106 CFU/spot and the addition of 5%
sheep blood to the agar markedly diminished the
activity of SCH-27899.
In a study conducted to derive preliminary
interpretive criteria for susceptibility testing of
SCH-27899 using the disk diffusion technique,
disk zone diameters of inhibition were correlated
with MICs of selected gram-positive and gram-
negative organisms.20 The greatest correlation
was seen with a test disk concentration of 5 µg.
For a break point of less than 2 µg/ml of SCH-
27899, susceptibility was defined as a zone larger
than 12 mm, intermediate susceptibility as a zone
of 10–11 mm, and resistance as a zone less than 9
mm.  Initially, due to limited solubility of SCH-
27899 in growth media, the manufacturer
recommended the E-test method to determine
susceptibilities.21 Subsequent investigations,
however, recorded excellent correlation for
susceptibility testing by broth microdilution and
agar dilution methods.21 The manufacturer of
SCH-27899 proposed susceptibility criteria, with
2 or less representing susceptibility, 4
representing intermediate susceptibility, and 8 or
greater indicating resistance.21
Resistance
The long-term utility of any antimicrobial
agent depends not only on its antimicrobial
activity and safety profile but also on the ease
with which resistance to the drug develops.
Although naturally occurring resistance to SCH-
27899 among organisms normally considered
susceptible to the agent has not been observed,
preliminary studies with this compound and the
everninomicins indicated the potential for
organisms to develop laboratory-induced
resistance.  Resistance occurred when S. aureus
strains that were initially susceptible to
everninomicin D were serially transfused into
increasing concentrations (2-fold dilutions) of
everninomicin D in liquid medium.2 The authors
recovered organisms that grew in 32 µg of
everninomicin D/ml.  Similarly, when strains of
MSSA, MRSA, and E. faecalis were exposed to
subinhibitory concentrations (1/16 MIC) of SCH-
27899, resistance developed, but in all cases it
did not exceed more than 4 times the original
MIC for the organism.7 In both studies,
resistance appeared in a slow, stepwise fashion.
Pharmacokinetics
The pharmacokinetics of SCH-27899 in
humans are best described by a three-compart-
ment model.  The compound is eliminated
primarily through hepatic transformation to
microbiologically inactive glucuronide and
sulfate conjugates, approximately 6% is
eliminated unchanged in urine, and 4% is
eliminated unchanged in feces.  Due to assay
limitations, the terminal elimination phase half-
life cannot be calculated reliably, but it was
reported to be approximately 10 hours.  The
agent has a high degree of protein binding
(96%) to albumin in vitro and appreciable
tissue distribution in vivo, although the exact
percentage bound to protein in vivo is
unknown.21 In a pharmacokinetic study in
humans, SCH-27899 was administered to
individuals with various degrees of renal
function.  Twenty subjects with creatinine
clearance ranging from below 15 ml/min/1.73 m2
(dialysis) to greater than 80 ml/min/1.73 m2 were
placed into five groups based on renal function
(4 patients/group).  Half-life was similar in all
groups, ranging from 8.34–9.83 hours, and the
compound was not dialyzable.22 These results
suggest that no dosage adjustment is required in
patients with renal insufficiency.  Early studies of
the closely related compound everninomicin D
found poor oral availability and erratic
intramuscular absorption.  As a result, the
intravenous route likely will be the only feasible
method of administration.23
Efficacy
Most available data concerning SCH-27899
come from in vitro and animal studies.  Studies
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using in vitro pharmacodynamic models
attempted to derive appropriate dosing regimens.
These models were designed to expose cultures
to a gradient of antibiotic concentrations to
simulate the drug’s serum pharmacokinetics.  In
one such model, various dosing regimens were
tested on isolates of MRSA, MRSE, S. haemolyticus,
penicillin-nonsusceptible S. pneumoniae,
ampicillin-resistant E. faecalis, Van-C-producing
Enterococcus gallinarum, and Van-A-producing E.
faecium.24 Concentrations of SCH-27899 were
used to simulate single dosages of 3, 6, and 10
mg/kg/day, and multiple-dose regimens of 3 and
6 mg/kg twice/day.  All dosages were effective in
achieving a kill of 4 log or better with MRSA or
MRSE strains with MIC of 1 µg/ml, whereas only
10 mg/kg/day and 6 mg/kg twice/day achieved
the same effects in S. haemolyticus strains with
MIC of 2 µg/ml.  In S. haemolyticus strains, other
regimens produced only 3 log killing.  In
penicillin-nonsusceptible S. pneumoniae, a 3 log
kill was achieved with 10 mg/kg/day and 6 mg/kg
twice/day.  Two-log killing was achieved with 6
and 10 mg/kg/day and 3 and 6 mg/kg twice/day.
Simulated dosages of 10 mg/kg/day and 6 and 3
mg/kg twice/day caused a 3 log kill in ampicillin-
resistant E. faecalis and Van-C-producing E.
gallinarum.  In the case of Van-A-producing E.
faecium, no killing was observed with any
regimen except 10 mg/kg/day, which produced a
kill of 1 log.  The authors concluded that
significant killing could be achieved for all
organisms tested with the exception of Van-A-
producing E. faecium.  Although such in vitro
models do not always predict in vivo efficacy,
they often are useful in deriving initial regimens
for preliminary human studies.
In an attempt to evaluate the drug’s potential
role in the treatment of catheter- and other
device-related infections, a strain of MRSA was
incubated with different sub-MIC concentrations
of everninomicin in combination with fosfomycin.7
Although the agents had no inhibitory effect at
concentrations tested, when the authors compared
viable sessile cells on the glass surface with or
without the agents after 7 days incubation at
37°C, the number of adherent cells was much
smaller in test cultures than in control cultures.
Unfortunately, the clinical implications of these
findings are unknown; the results were not
compared with other antimicrobials, and it is not
known whether these in vitro effects are
important in vivo.
The in vivo activity of SCH-27899 was studied
in several animal models.  In a murine model, the
agent was markedly effective in treating experi-
mental pneumonia caused by S. pneumoniae, and
in immunocompromised mice it prevented fatal
replication of Legionella pneumophila lung
infections.25, 26 In another murine model, its in
vivo effects were similar to those of vancomycin
and superior to those of placebo in a model of
hematogenous pulmonary infection induced by
MRSA enmeshed in agar beads.27
SCH-27899 was compared with ceftriaxone in
a phase II clinical trial involving 55 patients with
S. pneumoniae pneumonia.28 Patients were
randomized to receive 3 days of SCH-27899 (3 or
6 mg/kg/day intravenously) or ceftriaxone (2
g/day intravenously), followed by a 7-day course
of oral amoxicillin.  After 4 days, the clinical
response rate was 94% for the 3-mg/kg/day SCH-
27899 group and 100% for both the 6-mg/kg/day
SCH-27899 group and the ceftriaxone group.
Bacteriologic response rates were identical to
clinical response rates.  At the end of antibiotic
therapy (days 13–15), 100% of patients receiving
both SCH-27899 regimens had clinical cure or
improvement, compared with 94% of the
ceftriaxone group.  All groups achieved
eradication or presumed eradication at the end of
therapy.  All treatments were well tolerated;
adverse effects were reported in 4/17 patients
treated with SCH-27899 3 mg/kg/day, 7/18
treated with SCH-27899 6 mg/kg/day, and 7/20
treated with ceftriaxone.  Unfortunately, this
study was published as an abstract and did not
describe the adverse effects.
Toxicity
There are few published data regarding the
toxicity of SCH-27899.  In animal studies, targets
of toxicity were kidneys, liver, central nervous
system, adrenal glands, lymph nodes, lungs,
small intestine, and site of injection.21 In a
single-dose study in humans, the most common
adverse effects were dizziness, paresthesias,
headache, fatigue, weakness, and gastrointestinal
symptoms.  No dose-related adverse effects or
laboratory changes occurred.21 When several
doses were given to humans, toxicities were
injection site reactions, headache, loose stools,
fatigue, rhinitis, and gastrointestinal symptoms.
Increases in serum creatinine and decreases in
creatinine clearance were noted in 3/63 subjects.
These tended to occur after approximately 6 days
of therapy and returned to baseline after
approximately 10 days.  Increases in total
bilirubin were rarely reported, but they were
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considered mild to low and without clinical
significance.21
Potential Place in Therapy
Widespread administration of antimicrobial
agents has led to the development of resistance to
the action of many available antibiotics.  Gram-
positive infections, especially nosocomial
infections, are increasingly problematic.
Enterococci are intrinsically resistant to many
drugs, including fluoroquinolones, cephalo-
sporins, clindamycin, and aminoglycosides.29, 30
These organisms, in particular E. faecium and E.
faecalis, are associated with urinary tract
infections, wound infections, and bacteremias in
significant numbers of hospitalized patients.
Most alarming, with the emergence of VRE,
clinicians are faced with the potential for
infections that are resistant to virtually all
available agents.  Indeed, VRE are a global
problem and has diffuse geographic distribution
in the United States.30 In a multicenter study
using 1992 data, 23% of centers surveyed
reported VRE, and in a 1994 audit of centers not
reporting VRE in 1992, 61% reported subsequent
emergence of VRE.31 The optimal treatment of
VRE is not well defined.  Tetracycline, doxy-
cycline, newer fluoroquinolones, and chlor-
amphenicol have been tried, but both failure and
toxicities were reported with these agents.29, 30
The investigational RP-59500 is a combination
of two antibiotics of the streptogramin family
that have activity against both vancomycin-
susceptible and vancomycin-resistant strains of E.
faecium,  with less profound effects on E.
faecalis.29, 30, 32 The manufacturer of RP-59500 is
seeking approval from the Food and Drug
Administration.
Resistance among other strains of gram-
positive organisms is also widespread.
Staphylococci are commonly resistant to
penicillins and aminopenicillins, and resistance
of S. aureus and S. epidermidis to penicillinase-
resistant penicillins (oxacillin, methicillin)
increased drastically in the past several years.30
In addition, MRSA and MRSE can develop rapid
resistance to fluoroquinolones.30 Vancomycin
remains the drug of choice in the treatment of
MRSA and MRSE.  Although true vancomycin
resistance has not yet been reported in a clinical
isolate of S. aureus, the vancomycin resistance
gene was expressed in a strain of the organism,
and strains of VISA were reported in the United
States.30, 33
The frequency of penicillin-nonsusceptible
pneumococci increased dramatically in the past
several years.34 Pneumococcal resistance to
macrolides may occur, and resistance to the older
fluoroquinolones is possible.
SCH-27899 may prove to be useful in the
treatment of infections caused by VRE and other
highly resistant gram-positive organisms.  In
vitro susceptibility studies showed that it had
activity against VRE, MRSA, MRSE, VISA, and
penicillin-nonsusceptible pneumococci.8, 9, 24
Based on favorable results of animal studies and
phase II clinical trials, a double-blind, multi-
center, phase III trial of SCH-27899 in S. pneumoniae
pneumonia is in progress.  Also in progress are
additional phase II studies, one of which is
designed to evaluate the efficacy of the agent in
VRE bacteremia and another to test it in gram-
positive complicated skin, skin structure, and
intravenous catheter infections.  The ability to
induce laboratory resistance to both everninomicin
D and SCH-27899 warrants further study, as does
the role of combination therapy and various
dosages in the development of resistance.  If and
when the compound is available for compas-
sionate use, it may play a significant role in the
treatment of infections resistant to vancomycin.
Although it is not possible at this time to predict
its future role, the addition of new agents with
activity against organisms highly resistant to
conventional drugs is important.
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